Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort
- PMID: 30367449
- DOI: 10.1002/ijc.31950
Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort
Abstract
Age and tumor subtype are prognostic factors for breast cancer survival, but it is unclear which matters the most. We used population-based data to address this question. We identified 21,384 women diagnosed with breast cancer at ages 20-89 between 2005 and 2015 in the Cancer Registry of Norway. Subtype was defined using estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2) status as luminal A-like (ER+PR+HER2-), luminal B-like HER2-negative (ER+PR-HER2-), luminal B-like HER2-positive (ER+PR+/-HER2+), HER2-positive (ER-PR-HER2+) and triple-negative (TNBC) (ER-PR-HER2-). Cox regression estimated hazard ratios (HR) for breast cancer-specific 7-year survival by age and subtype, while adjusting for year, grade, TNM stage and treatment. Young women more often had HER2-positive and TNBC tumors, while elderly women (70-89) more often had luminal A-like tumors. Compared to age 50-59, young women had doubled breast cancer-specific mortality rate (HR = 2.26, 95% CI 1.81-2.82), while elderly had two to five times higher mortality rate (70-79: HR = 2.25, 1.87-2.71; 80-89: HR = 5.19, 4.21-6.41). After adjustments, the association was non-significant among young women but remained high among elderly. Young age was associated with increased breast cancer-specific mortality among luminal A-like subtype, while old age was associated with increased mortality in all subtypes. Age and subtype were strong independent prognostic factors. The elderly always did worse, also after adjustment for subtype. Tumor-associated factors (subtype, grade and stage) largely explained the higher breast cancer-specific mortality among young. Future studies should address why luminal A-like subtype is associated with a higher mortality rate in young women.
Keywords: IHC markers; age; breast cancer; clinical subtype; survival.
© 2018 UICC.
Comment in
-
Detection by screening introduces biases into survival estimates for luminal A-like breast cancer patients.Int J Cancer. 2020 Mar 15;146(6):1764-1766. doi: 10.1002/ijc.32697. Epub 2019 Nov 15. Int J Cancer. 2020. PMID: 31576554 No abstract available.
-
Author's reply to: "Detection by screening introduces biases into survival estimates for luminal A-like breast cancer patients".Int J Cancer. 2020 Mar 15;146(6):1767-1768. doi: 10.1002/ijc.32699. Epub 2019 Nov 15. Int J Cancer. 2020. PMID: 31576557 No abstract available.
Similar articles
-
Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.J Surg Res. 2019 Apr;236:288-299. doi: 10.1016/j.jss.2018.11.028. Epub 2018 Dec 27. J Surg Res. 2019. PMID: 30694768
-
Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.Arch Iran Med. 2016 Oct;19(10):680-686. Arch Iran Med. 2016. PMID: 27743431
-
Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.Breast Cancer Res Treat. 2017 Oct;165(3):743-750. doi: 10.1007/s10549-017-4383-5. Epub 2017 Jul 8. Breast Cancer Res Treat. 2017. PMID: 28689363
-
Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective.Ann Oncol. 2012 Aug;23 Suppl 6:vi19-22. doi: 10.1093/annonc/mds190. Ann Oncol. 2012. PMID: 23012297 Review.
-
Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer.Breast Cancer Res Treat. 2019 Jul;176(1):27-36. doi: 10.1007/s10549-019-05233-9. Epub 2019 Apr 17. Breast Cancer Res Treat. 2019. PMID: 30997625 Free PMC article. Review.
Cited by
-
Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance.Exp Mol Med. 2024 Nov 1. doi: 10.1038/s12276-024-01332-w. Online ahead of print. Exp Mol Med. 2024. PMID: 39482530
-
Populations of triple negative and hormone receptor positive HER2 negative breast tumors share immune gene profiles.Res Sq [Preprint]. 2024 Aug 2:rs.3.rs-4542494. doi: 10.21203/rs.3.rs-4542494/v1. Res Sq. 2024. PMID: 39149486 Free PMC article. Preprint.
-
The prevalence and correlates of comorbidities among patients with cancer attending a tertiary care cancer center in South India: An analytical cross-sectional study.Cancer Res Stat Treat. 2023;6(4):526-533. doi: 10.4103/crst.crst_93_23. Epub 2023 Dec 23. Cancer Res Stat Treat. 2023. PMID: 38826774 Free PMC article.
-
Follow-up Routines Matter for Adherence to Endocrine Therapy in the Adjuvant Setting of Breast Cancer.Breast Cancer (Auckl). 2024 Apr 15;18:11782234241240171. doi: 10.1177/11782234241240171. eCollection 2024. Breast Cancer (Auckl). 2024. PMID: 38628960 Free PMC article.
-
Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics.Breast Cancer Res Treat. 2024 Jun;205(3):619-631. doi: 10.1007/s10549-024-07280-3. Epub 2024 Mar 25. Breast Cancer Res Treat. 2024. PMID: 38526687 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous